Showing results (241-250 of 290) with videos related to
Sort By:
Pageof 29
Molecular Cancer Therapeutics|March 11, 2014
Concordance of genomic alterations between primary and recurrent breast cancerFunda Meric-Bernstam, Garrett M Frampton, Jaime Ferrer-Lozano, et al.JCO Precision Oncology|February 1, 2022
Atypical RAS Mutations in Metastatic Colorectal CancerFilippo Pietrantonio, Rona Yaeger, Alexa B Schrock, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic ProfilingAlexa B Schrock, Shuyu D Li, Garrett M Frampton, et al.Cancer Discovery|September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsHaiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.Genome Medicine|April 20, 2017
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenZachary R Chalmers, Caitlin F Connelly, David Fabrizio, et al.European Urology|January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the BladderAndrea Necchi, Russell Madison, Daniele Raggi, et al.Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.Proceedings of the National Academy of Sciences of the United States of America|December 18, 2014
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsRaajit Rampal, Jihae Ahn, Omar Abdel-Wahab, et al.Proceedings of the National Academy of Sciences of the United States of America|July 10, 2012
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2013
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinomaJeffrey S Ross, Kai Wang, Laurie M Gay, et al.Pageof 29